Peter A. Prieto
A5036869327- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Immunotherapy and Immune Responses
- Melanoma and MAPK Pathways
- Cutaneous Melanoma Detection and Management
- Reconstructive Surgery and Microvascular Techniques
- Cancer Genomics and Diagnostics
- Breast Implant and Reconstruction
- Gut microbiota and health
- Cancer, Stress, Anesthesia, and Immune Response
- Breast Cancer Treatment Studies
- Ferroptosis and cancer prognosis
- Immune cells in cancer
- Cancer Cells and Metastasis
- Immune Cell Function and Interaction
- Peptidase Inhibition and Analysis
- Click Chemistry and Applications
- Colorectal Cancer Treatments and Studies
- Inflammatory Biomarkers in Disease Prognosis
- Cancer Research and Treatments
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Radiomics and Machine Learning in Medical Imaging
- AI in cancer detection
- Diabetes and associated disorders
- Mesenchymal stem cell research
Theravance Biopharma (United States)
2024-2025
University of Rochester Medical Center
2018-2024
The University of Texas MD Anderson Cancer Center
2016-2023
University of Rochester
2019-2021
Novartis (Switzerland)
2016
GlaxoSmithKline (United Kingdom)
2016
Illumina (United States)
2016
University of the Basque Country
2014
Yale University
2012-2013
Center for Cancer Research
2012
Preclinical mouse models suggest that the gut microbiome modulates tumor response to checkpoint blockade immunotherapy; however, this has not been well-characterized in human cancer patients. Here we examined oral and of melanoma patients undergoing anti-programmed cell death 1 protein (PD-1) immunotherapy (
Immune checkpoint blockade represents a major breakthrough in cancer therapy; however, responses are not universal. Genomic and immune features pretreatment tumor biopsies have been reported to correlate with response patients melanoma other cancers, but robust biomarkers identified. We studied cohort of metastatic initially treated cytotoxic T-lymphocyte-associated antigen-4 (CTLA4) (n = 53) followed by programmed death-1 (PD-1) at progression 46), analyzed signatures longitudinal tissue...
Immune checkpoint blockade produces clinical benefit in many patients. However, better biomarkers of response are still needed, and mechanisms resistance remain incompletely understood. To address this, we recently studied a cohort melanoma patients treated with sequential against cytotoxic T lymphocyte antigen-4 (CTLA-4) followed by programmed death receptor-1 (PD-1) identified immune markers resistance. Building on these studies, performed deep molecular profiling including cell receptor...
Abstract Purpose: Treatment with ipilimumab can cause objective tumor responses in patients metastatic melanoma. We have treated 177 evaluable three clinical trials and long-term follow-up to evaluate the durability of responses. Experimental Design: Patients melanoma were from 2002 2005. In protocol 1, 56 received gp100 peptides. 2, 36 interleukin-2. 3, 85 intrapatient dose-escalation randomized receive analyzed their survival data. Results: With median for protocols 3 being 92, 84, 71...
Abstract Purpose: Tumor-infiltrating lymphocytes (TIL) and interleukin (IL)-2 administered following lymphodepletion can cause the durable complete regression of bulky metastatic melanoma in patients refractory to approved treatments. However, generation a unique tumor-reactive TIL culture for each patient may be prohibitively difficult. We therefore investigated clinical immunologic impact unscreened, CD8+ enriched “young” TIL. Experimental Design: Methods were developed generating that...
Appreciation for genomic and immune heterogeneity in cancer has grown though the relationship of these factors to treatment response not been thoroughly elucidated. To better understand this, we studied a large cohort melanoma patients treated with targeted therapy or checkpoint blockade (n = 60). Heterogeneity therapeutic responses via radiologic assessment was observed majority patients. Synchronous metastases were analyzed deep profiling, revealed substantial all studied, considerable...
Adoptive cell therapy using tumor-infiltrating lymphocytes (TIL) can mediate objective and durable tumor regressions in patients with metastatic melanoma. CD8+ tumor-reactive TIL are well studied humans animals, yet the function of CD4+ T patient treatments remains controversial. We recently demonstrated that TILs not necessary for responses patients. Coinfusion tumor-specific CD4 may enhance or increase durability regressions, but number is unknown. screened 44 CD8+-depleted vitro...
Over 80% of pancreatic ductal adenocarcinoma (PDA) patients are diagnosed with non-resectable late-stage disease that lacks effective neoadjuvant therapies. Stereotactic body radiation therapy (SBRT) has shown promise as an emerging approach for treating PDA, and here, we report its combination local interleukin-12 (IL-12) microsphere (MS) immunotherapy results in marked tumor reduction cures multiple preclinical mouse models PDA. Our findings demonstrate increase intratumoral interferon...
Adoptive cell therapy (ACT) using tumor-infiltrating lymphocytes (TIL) for metastatic melanoma has shown objective response rates as high 72%. The successful application of this requires the selection unique tumor-reactive lymphocyte cultures each patient. This is a technically and logistically difficult undertaking, patients who do not have TIL are considered eligible treatment. To simplify methods generation extend TIL-based immunotherapy to additional patients, were developed use...
We have made major advances in the treatment of melanoma through use targeted therapy and immune checkpoint blockade; however, clinicians are posed with therapeutic dilemmas regarding timing sequence therapy. There is a growing appreciation impact antitumor responses to these therapies, we performed studies test hypothesis that clinical patterns infiltrates differ at progression on treatments. observed rapid kinetics patients compared blockade. To gain insight into possible mechanisms behind...
9508 Background: Outcomes for pts with mMEL remain sobering despite access to available immunotherapies as the majority of are resistant or become refractory checkpoint blockade no approved treatments. CXCR1 and CXCR2 (CXCR1/2) signaling mediate myeloid immunosuppression MEL growth, inversely correlating anti-PD-1 response pt survival. SX-682 is an oral allosteric inhibitor CXCR1/2. As a single agent, increases tumor CD8+ T cell infiltration inhibits growth in mouse MEL. Methods: This phase...
Metastatic renal cell carcinoma (RCC) to the liver portrays a poor prognosis and directed therapy remains controversial. We aimed determine potential selection criteria for patients who might benefit from this strategy.We evaluated 247 consecutive with RCC metastatic prospectively maintained database.Eighteen received (18/247, 7%). Ten underwent resection (10/247, 4%) eight radiofrequency ablation (RFA, 8/247, 3%). All were rendered free of disease in liver. Five had synchronous resections...
Background: Approximately 50% of melanomas harbor BRAF mutations. Treatment with +/− MEK inhibition is associated favorable changes in the tumor microenvironment thus providing rationale for combining targeted agents immunotherapy.Methods: Patients unresectable Stage III or IV BRAFV600E mutant melanoma were enrolled a single-center prospective study (n = 6). eligible to receive two courses HD-IL-2 and vemurafenib twice daily. The primary endpoint was progression-free survival (PFS) secondary...
8544 Background: We have previously shown objective clinical responses in patients with metastatic melanoma treated CTLA-4 blockade using ipilimumab. 179 3 separate trials and now long-term follow-up to evaluate the durability unique features of this immunotherapy. Methods: A total were trials: In Protocol 1, 56 received ipilimumab gp100 peptide vaccines. 2, 36 high-dose interleukin-2 (IL-2). 3, 87 intra-patient dose escalation randomized receive peptides. updated analyzed survival data for...
2 Background: Tremendous advances have been made in cancer therapy through the use of immune checkpoint blockade, although responses are not always durable. There is a growing appreciation role microbiome cancer-related outcomes and recent evidence murine models suggests that modulation gut may enhance to blockade melanoma. However this has investigated patients. Here, we demonstrate differential bacterial “signatures” exist responders (R) non-responders (NR) anti-PD1 at baseline, insights...